You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,obesity* and,body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI equal to or greater than 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).,Table 1 BMI cut-off points for obesity (equal to or greater than 95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria),Age (years) BMI (kg/m2) at 95th Percentile Males Females,12 24.2 25.2,12.5 24.7 25.7,13 25.1 26.3,13.5 25.6 26.8,14 26.0 27.2,14.5 26.4 27.7,15 26.8 28.1,15.5 27.2 28.5,16 27.5 28.9,16.5 27.9 29.3,17 28.2 29.6,17.5 28.6 30.0,Reduction in risk of major adverse cardiovascular events,Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) equal to or greater than 27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties Clinical trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,obesity* and,body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI equal to or greater than 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).,Table 1 BMI cut-off points for obesity (equal to or greater than 95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria),Age (years) BMI (kg/m2) at 95th Percentile Males Females,12 24.2 25.2,12.5 24.7 25.7,13 25.1 26.3,13.5 25.6 26.8,14 26.0 27.2,14.5 26.4 27.7,15 26.8 28.1,15.5 27.2 28.5,16 27.5 28.9,16.5 27.9 29.3,17 28.2 29.6,17.5 28.6 30.0,Reduction in risk of major adverse cardiovascular events,Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) equal to or greater than 27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties Clinical trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,obesity* and,body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI equal to or greater than 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).,Table 1 BMI cut-off points for obesity (equal to or greater than 95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria),Age (years) BMI (kg/m2) at 95th Percentile Males Females,12 24.2 25.2,12.5 24.7 25.7,13 25.1 26.3,13.5 25.6 26.8,14 26.0 27.2,14.5 26.4 27.7,15 26.8 28.1,15.5 27.2 28.5,16 27.5 28.9,16.5 27.9 29.3,17 28.2 29.6,17.5 28.6 30.0,Reduction in risk of major adverse cardiovascular events,Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) equal to or greater than 27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties Clinical trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,obesity* and,body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI equal to or greater than 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).,Table 1 BMI cut-off points for obesity (equal to or greater than 95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria),Age (years) BMI (kg/m2) at 95th Percentile Males Females,12 24.2 25.2,12.5 24.7 25.7,13 25.1 26.3,13.5 25.6 26.8,14 26.0 27.2,14.5 26.4 27.7,15 26.8 28.1,15.5 27.2 28.5,16 27.5 28.9,16.5 27.9 29.3,17 28.2 29.6,17.5 28.6 30.0,Reduction in risk of major adverse cardiovascular events,Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) equal to or greater than 27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties Clinical trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see Section 5.1 Pharmacodynamic Properties Clinical trials).,Adolescents,Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,obesity* and,body weight above 60 kg,Treatment with Wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*Obesity (BMI equal to or greater than 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1).,Table 1 BMI cut-off points for obesity (equal to or greater than 95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria),Age (years) BMI (kg/m2) at 95th Percentile Males Females,12 24.2 25.2,12.5 24.7 25.7,13 25.1 26.3,13.5 25.6 26.8,14 26.0 27.2,14.5 26.4 27.7,15 26.8 28.1,15.5 27.2 28.5,16 27.5 28.9,16.5 27.9 29.3,17 28.2 29.6,17.5 28.6 30.0,Reduction in risk of major adverse cardiovascular events,Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) equal to or greater than 27kg/m2, and without established Type 1 or Type 2 diabetes (see Section 5.1 Pharmacodynamic Properties Clinical trials).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
